Four-pronged partnership to produce automated systems for CRISPR

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags: Oxford Genetics, Gene editing, Human genome, CRISPR, Partnership, Mammalian cell culture, Cell line

Oxford Genetics and Sphere Fluidics to partner, alongside additional biopharma organizations, to develop automated systems for high-throughput gene editing in mammalian cell lines.

Joining Oxford Genetics and Sphere Fluidics will be joined in this by Twist Bioscience and the University of Edinburgh. Oxford Genetics and the University will be working together to provide input on the developing products.

Oxford Genetics has been working to develop automated laboratory processes to facilitate intelligent data handling, and this project serves as a continuation of that initiative. In August 2018, Oxford Genetics signed a supply and licensing agreement​ to employ its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

Tom Payne, CSO of Oxford Genetics, said in a statement, “Gene editing, particularly CRISPR technologies, have revolutionized the way scientists are able to engineer mammalian cells for a wide variety of applications. While these technologies are highly efficient, there is a requirement to further optimize the way laboratories deliver the CRISPR tools to cells and interrogate the resultant products.”

Per the agreement, Sphere Fluidics will act as lead partner and take on production, Oxford Genetics and the University of Edinburgh will provide input into industrial and application-specific needs for the products designed for multiplexed gene editing workflows.

Sphere Fluidics said in a statement that it plans to use this partnership to develop a desktop system to miniaturize and automate the genome editing of single cells.

This system will enable scientists to easily perform automated genome editing and create new cell lines and valuable biomedical products,”​ said Frank Craig, CEO of Sphere Fluidics.

Twist Bioscience will contribute DNA synthesis capabilities and necessary reagents for the project.

The delivery of tools can increase throughput and reduce timelines, which in turn has the ability to create new avenues of research and commercial applications, according to Payne.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Related suppliers

Follow us

Products

View more

Webinars